TQ-B3234

TQ-B3234 is a small-molecule drug developed by Chia Tai Tianqing Pharmaceutical. The sponsor describes its target as MEK1/2 (mitogen-activated protein kinase 1/2), which OnCo does not yet have a target page for. The sponsor states: A selective MEK1/2 inhibitor, dosed as an oral capsule, that inhibits the MEK protein (an upstream regulator of the ERK pathway) and is being tested against placebo for symptomatic, inoperable plexiform neurofibromas in neurofibromatosis type 1. ClinicalTrials.gov describes the intervention as: TQ-B3234 is an antitumor molecular targeted drug, a selective mitogen-activated protein kinase 1 and 2 (MEK1/2) inhibitor. It primarily inhibits the mitogen-activated protein kinase (MEK) protein (an upstream regulator of the extracellular. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT07407803 (Evaluation of TQ-B3234 Capsules in Patients With Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated Plexiform Neurofibromas), in rare cancers of childhood. The largest, NCT07407803, plans to enrol 177 participants with primary completion expected 2027-12. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.